Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Renata UrsuDidier MailletCatherine BelinChristine MoroniStefania CuzzubboVictoria VernierLila Sirven-VillarosChristophe CarreauRoberta Di BlasiCatherine ThieblemontAntoine F CarpentierPublished in: Neurology (2022)
In conclusion, no significant neurocognitive or neurologic disorders were observed in this cohort of patients, 2 years after treatment with anti-CD19 CAR T cells.